"Potential target vedolizumab/entyvio trough levels were 37.1 μg/mL at week 6 during induction, 18.4 μg/mL at week 14 after induction, and 12.7 μg/mL during maintenance treatment"
"Data from the two largest available real-world cohorts to date confirmed a link between higher vedolizumab exposure and achieving better outcomes"
"Belgian study, vedolizumab/entyvio trough levels > 30 μg/mL at week 2, > 24 μg/mL at week 6, and > 14 μg/mL during maintenance therapy, correlated with higher clinical and endoscopic effectiveness endpoints in IBD patients"
Source: Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6505179/